Literature DB >> 22528938

Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Teresa Granato1, Cecilia Midulla, Flavia Longo, Barbara Colaprisca, Luigi Frati, Emanuela Anastasi.   

Abstract

The aim of this study was to investigate the role of biomarkers CA125, HE4, and CA72.4 at diagnosis and throughout the follow-up in patients with epithelial ovarian cancer (EOC). Thirty-nine patients with EOC were deemed eligible, and 20 were followed up. CA125, HE4, and CA72.4 serum levels were determined for all patients at initial diagnosis of EOC. Among these patients, the number of cases with an elevated level of each individual marker was CA125 77 %, HE4 85 %, and CA72.4 72 %. A statistically significant difference was observed between the level of HE4 when compared to CA72.4 (p < 0.02). In the follow-up phase, we observed tumor marker levels fluctuating according to response to chemotherapy. When combining two out of the three biomarkers together, we observed increased values of CA125 and CA72.4 in 55 % of the patients, increased values of CA125 and HE4 in 65 % of the patients, and finally increased HE4 and CA72.4 in 75 % of the patients. A statistically significant difference was observed when combining HE4 and CA72.4, but not CA125 and CA 72.4 (p < 0.002). In conclusion, our study demonstrates that the association of three biomarkers CA125, HE4, and CA72.4 provides a valuable contribution in the follow-up of EOC patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528938     DOI: 10.1007/s13277-012-0381-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.

Authors:  Mirjam J A Engelen; Henrike E Kos; Pax H B Willemse; Jan G Aalders; Elisabeth G E de Vries; Michael Schaapveld; Renee Otter; Ate G J van der Zee
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

2.  The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory.

Authors:  Catharine M Sturgeon; Michael J Duffy; Graeme Walker
Journal:  Ann Clin Biochem       Date:  2011-07       Impact factor: 2.057

3.  Estimates of the worldwide incidence of 25 major cancers in 1990.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

4.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

Review 5.  Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review.

Authors:  Lidia Rosi Medeiros; Daniela Dornelles Rosa; Maria Inês da Rosa; Mary Clarisse Bozzetti
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2008-11-07       Impact factor: 2.435

6.  Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.

Authors:  D X Chen; P E Schwartz; X G Li; Z Yang
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

7.  Serum and tissue measurements of CA72-4 in ovarian cancer patients.

Authors:  Y Negishi; H Iwabuchi; H Sakunaga; M Sakamoto; K Okabe; H Sato; G Asano
Journal:  Gynecol Oncol       Date:  1993-02       Impact factor: 5.482

Review 8.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.

Authors:  Mark Harries; Martin Gore
Journal:  Lancet Oncol       Date:  2002-09       Impact factor: 41.316

Review 9.  CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Chunqiao Tian; Maurie Markman; Richard Zaino; Robert F Ozols; William P McGuire; Franco M Muggia; Peter G Rose; David Spriggs; Deborah K Armstrong
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

10.  The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer.

Authors:  S T Fayed; S M Ahmad; S K Kassim; A Khalifa
Journal:  Dis Markers       Date:  1998-11       Impact factor: 3.434

View more
  26 in total

1.  Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Authors:  Yan Zhang; Chunxia Qiao; Lian Li; Xuye Zhao; Yali Li
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

Review 2.  Association between NQO1 C609T polymorphism and prostate cancer risk.

Authors:  Zihan Sun; Yuling Cui; Jing Pei; Zhiqiang Fan
Journal:  Tumour Biol       Date:  2014-05-17

3.  Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

Authors:  Liang Li; Xuening Zhang; Qinglai Xia; Hui Ma; Li Chen; Wenjing Hou
Journal:  Tumour Biol       Date:  2014-01-12

Review 4.  Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.

Authors:  Stella Capriglione; Daniela Luvero; Francesco Plotti; Corrado Terranova; Roberto Montera; Giuseppe Scaletta; Teresa Schirò; Gianmarco Rossini; Pierluigi Benedetti Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2017-08-20       Impact factor: 3.064

5.  Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.

Authors:  Yuling Cui; Yanhua Jing; Zihan Sun
Journal:  Tumour Biol       Date:  2013-11-28

6.  NFAT Overexpression Correlates with CA72-4 and Poor Prognosis of Ovarian Clear-Cell Carcinoma Subtype.

Authors:  Bing Xin; Kai-Qiang Ji; Yi-Si Liu; Xiao-Dong Zhao
Journal:  Reprod Sci       Date:  2020-10-30       Impact factor: 3.060

Review 7.  Role of biomarkers for early detection of ovarian cancer recurrence.

Authors:  Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco
Journal:  Gland Surg       Date:  2020-08

8.  The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Authors:  Mani Nassir; Jun Guan; Hrvoje Luketina; Timo Siepmann; Irena Rohr; Rolf Richter; Dan Cacsire Castillo-Tong; Robert Zeillinger; Ignace Vergote; Els Van Nieuwenhuysen; Nicole Concin; Christian Marth; Christina Hall; Sven Mahner; Linn Woelber; Jalid Sehouli; Elena Ioana Braicu
Journal:  Tumour Biol       Date:  2015-09-29

9.  CLEIA CA125 evidences: good analytical performance avoiding "Hook effect".

Authors:  R Falzarano; V Viggiani; S Michienzi; B Colaprisca; F Longo; L Frati; E Anastasi
Journal:  Tumour Biol       Date:  2012-11-01

10.  MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.

Authors:  Bairong Xia; Huiyan Li; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2016-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.